HSCSW · Insider Trading
HeartSciences Inc. Warrant
Every open-market purchase and sale reported by HSCSW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-12 | Bruce Bent | Director | A | +15,000 deriv. | — |
| 2026-01-12 | David R. Wells | Director | A | +15,000 deriv. | — |
| 2025-12-22 | Brian Szymczak | Director | A | +15,000 deriv. | — |
| 2025-12-22 | Danielle Watson | See Remarks | A | +15,000 deriv. | — |
| 2025-12-22 | Mark T Hilz | See Remarks | A | +45,000 deriv. | — |
| 2025-11-28 | Andrew Simpson | See Remarks | A | +70,000 | — |
| 2025-07-30 | Mark T Hilz | COO, Secretary and Director | Sell | −4,416 | −$15.62K |
| 2025-07-14 | Bruce Bent | Director | A | +25,000 deriv. | — |
| 2025-07-11 | David R. Wells | Director | A | +25,000 deriv. | — |
| 2025-07-11 | Danielle Watson | See Remarks | A | +25,000 deriv. | — |
| 2025-07-11 | Brian Szymczak | Director | A | +25,000 deriv. | — |
| 2025-07-11 | Mark T Hilz | See Remarks | A | +281,250 deriv. | — |
| 2025-07-11 | Andrew Simpson | See Remarks | A | +343,750 deriv. | — |
| 2025-01-23 | Bruce Bent | Director | A | +6,000 deriv. | — |
| 2025-01-21 | Brian Szymczak | Director | A | +6,000 deriv. | — |
| 2025-01-21 | David R. Wells | Director | A | +6,000 deriv. | — |
| 2025-01-21 | Danielle Watson | See Remarks | A | +9,000 deriv. | — |
| 2025-01-21 | Andrew Simpson | See Remarks | A | +45,000 deriv. | — |
| 2025-01-21 | Mark T Hilz | See Remarks | A | +45,000 deriv. | — |
| 2024-08-14 | Andrew Simpson | See Remarks | J | +17 | — |
| 2023-03-22 | Danielle Watson | See Remarks | A | +75,000 deriv. | — |
| 2023-03-22 | Mark T Hilz | See Remarks | A | +300,000 deriv. | — |
| 2023-03-22 | Brian Szymczak | Director | A | +50,000 deriv. | — |
| 2023-03-22 | David R. Wells | Director | A | +50,000 deriv. | — |
| 2023-03-22 | Andrew Simpson | See Remarks | A | +300,000 deriv. | — |
| 2023-03-22 | Bruce Bent | Director | A | +50,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Andrew Simpson | See Remarks | 74,382 | $4.54K |
| Mark T Hilz | See Remarks | 4,793 | $292 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HSCSW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.